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The herb Butea monosperma constitutes several human health beneﬁcial components, which are mostly
studied for their anticancer effects. In this study, the activity of n-butanol fractions of B. monosperma
ﬂoral extract was examined on inhibiting aberrant crypt foci (ACF) formation in azoxymethane induced
Wistar albino rats. The n-butanol extracts (150 mg/kg) decreased the ACF formation (per rat) by 92% and
78% in short- and long-term in vivo treatments, respectively. All the compounds in the n-butanol extract
were isolated and puriﬁed using column and reverse-phase high pressure liquid chromatography (HPLC).
Their structures were characterized using UV–visible spectroscopy, nuclear magnetic resonance (NMR)
and electrospray–ionisation mass spectrometry (ESI–MS) to determine important ﬂavonoids, namely
isocoreopsin, butrin and isobutrin. These compounds were studied for their free radical scavenging and
anticancer activities. The compound isocoreopsin showed signiﬁcantly greater efﬁcacy in cell death on
human colon and liver cancer cell lines (50 μg/mL in HT-29 and 100 μg/mL in HepG2) than butrin
(100 μg/mL in HT-29 and 500 μg/mL in HepG2) and isobutrin (80 μg/mL in HT-29 and 150 μg/mL in
HepG2). These results suggest that isocoreopsin, butrin and isobutrin are the important key compounds
for the chemoprevention of colon cancer and isocoreopsin can be considered as a promising novel drug.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In humans, colorectal cancer (CRC) and hepatocellular carci-
noma (HCC) rank the second and third most common causes of
cancer-related death in most developed countries around the
world [1,2]. The incidence of liver cancer is steadily increasing due
to obesity, diabetes, alcohol intake, cirrhosis and rise of hepatitis C
virus infection [3]. Surgery and chemotherapy are available for
HCC treatment but the multidrug resistance (MDR-1) gene prop-
erties and their related protein expression always pose a challenge
for the treatment of cancer [4].
Aberrant crypt foci (ACF) in colon has been proposed as pre-
cancerous lesions for CRC and an appropriate biomarker for identify-
ing modulatory effects of xenobiotic on colon carcinogenesis [5]. The
simple interpretation is that the identiﬁcation of preneoplastic lesions
may lead to the execution of successful chemoprevention studies in
cancer treatment [6]. Interestingly, nutrients derived from plant source
play a vital role in prevention and treatment of many diseases by
stimulating antioxidants. Over several years, the accumulatingon and hosting by Elsevier B.V. Th
University.evidence suggested that phenolic compounds have potential anti-
oxidant activity with the presence of ﬂavonoids [7]. Earlier reports of
medicinal plants and their prospective effects on many diseases and
disorders have revealed a growing interest in the herbal drug for its
divergent medicinal purpose [8].
Several studies suggest that the methanolic and acetone extract
of Butea monosperma (B. monosperma) ﬂowers have antibacterial,
antifungal, anti-inﬂammatory and wound healing properties [9–
11]. In addition to this, petroleum ether extracts and ethanolic
extracts of B. monosperma ﬂowers possess antidiabetic, antipyretic
and radical scavenging activities with respect to in vivo and in
vitro models [12,13].
Ethanolic extract of B. monosperma leaves increased the antic-
ancer activity against Ehrlich ascites carcinoma (EAC) in Swiss al-
bino mice [14]. Similarly, aqueous extract of B. monosperma ﬂow-
ers was found to be effective on HBV-related X15-myc mouse
model of HCC [15]. Further, it was reported that the aqueous ex-
tract of B. monosperma ﬂowers has anticancer activity by stimu-
lating proapoptotic function and inhibiting cell growth, anti-oxi-
dant and free radical scavenging activities in vitro study [16]. As
mentioned previously, extracts of B. monosperma ﬂowers exhibit
potential anticancer activity due to its ﬂavonoids such as butin,
butein, butrin, isobutrin, palasitrin, coreopsin, isocoreopsin,is is an open access article under the CC BY-NC-ND license
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Moreover, the earlier reports indicated that the overexpression of
Wnt signaling pathway played a vital role in CRC and HCC devel-
opment through the upregulation of early growth response genes
[18–20]. However, the reports suggested that B. monosperma may
have a suppressive effect on early growth response genes and thus
mechanism needs further investigation for better understanding.
This paper details the effect of the n-butanol extract of
B. monosperma ﬂowers on colon cancer in azoxymethane (AOM)
induced rat model and the isolation of all the three active com-
pounds, namely isocoreopsin, butrin and isobutrin, by chromato-
graphy methods and structural validation using nuclear magnetic
resonance (NMR), Fourier transform infrared spectroscopy (FTIR)
and electrospray–ionisation mass spectrometry (ESI–MS). Further,
it strived a clear idea on the n-butanol extract (NBE) of B. mono-
sperma ﬂowers and their individual effect on hepatocarcinoma and
adenoma cancer cell lines.2. Experimental
2.1. Chemicals and reagents
Naringenin (5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihy-
drochromen-4-one), ellagic acid, 2,2-diphenyl-1-picrylhydrazyl
(DPPH) and AOM were obtained from Sigma–Aldrich Co (Saint
Louis, MO, USA). Sodium carbonate, aluminium chloride, po-
tassium acetate, silica gel (60–120 mesh) and HPLC grade acet-
onitrile were obtained from Merck & Co (USA). Dulbecco's mod-
iﬁed Eagle's medium (DMEM), 10% fetal bovine serum (10% FBS),
penicillin/streptomycin and DMSO (cell culture grade) were pur-
chased from Hi Media Laboratories, Mumbai, India. All other
chemicals and solvents used were of analytical grade/better.
2.2. Instrumentation
The UV spectra were recorded with double beam UV-visible
spectrophotometer. The FTIR spectra of the separated compounds
were conﬁrmed on JASCO FTIR Spectrophotometer (USA). NMR
spectrumwas revealed in DMSO-d6 on a Bruker Avance 500 or 600
spectrometer (Switzerland). ESI–MS was recorded on Waters
UPLC-TQD (USA). Silica gel (60–120 mesh) was used to separate
the various compounds by column chromatography against me-
thanol and ethyl acetate of analytical grade (Merck & Co, USA).
Puriﬁcation of the compounds was achieved by pre-coated silica
gel F254 TLC. Adsorption data for the free radical scavenging ac-
tivity was measured by using Shimadzu 800 spectroscopy (Japan).
2.3. Plant material
Butea monosperma (Lam.) Taub. ﬂowers were collected from the
Palkalai Perur campus of Bharathidasan University, Tiruchirappalli,
Tamil Nadu, India. A voucher specimen was conﬁrmed and de-
posited in the Department of Plant Science, Bharathidasan Uni-
versity (BDUT 1001).
2.4. Extraction of B. monosperma ﬂowers
Air dried B. monosperma ﬂowers were ﬁnely powdered and
extracted with methanol in soxhlet apparatus for 24 h. Then the
extract was concentrated under reduced pressure in a rotator
evaporator, which was partitioned with water and ethyl acetate
(EtOAc). After partition, the persistent water phase was treated
with n-butanol (3 times) and dried with sodium sulphate. Sub-
sequently, the NBE was concentrated by rotator evaporator and
stored at 4 °C [21].2.5. Isolation of active compounds from B.monosperma ﬂowers by
column chromatography
The dried NBE of B. monosperma ﬂowers was subjected to Si-
lica-100 macroporous adsorption resin column. The column was
rinsed with EtOAc (discarded), then EtOAc with various con-
centrations of MeOH (5%, 15%, 30%, 50%, 70%, and 95%, v/v) was
used as mobile phase to acquire three fractions successively.
2.5.1. High performance thin layer chromatography (HPTLC)
The collected fractions were dissolved in HPLC grade methanol
(1 mg/mL) and subjected to HPTLC. The sample was spotted on
pre-coated silica gel F254 TLC plates using CAMAG Linomat V
automatic sample Spotter and the plates were developed in EtOAc
methanol (30:70, v/v) solvent system. The plates were scanned in
TLC scanner 3 (CAMAG) at 254 nm. The Rf values, spectra, Lambda
max and peak areas of the resolved bands were recorded and re-
lative percentage area of each band was calculated from peak
areas.
2.5.2. High pressure liquid chromatography (HPLC)
Among the three collected fractions, fraction II was analyzed on
a Waters 2545 HPLC-photodiode array system (Quaternary gra-
dient module) with symmetry C18 column (250 mm × 4.6 mm,
5 μm) at a column temperature of 28 °C. Two mobile phases, A and
B, were used. Mobile phase A was 0.1% (v/v) phosphoric acid in
water, while mobile phase B was acetonitrile. A ratio of 70% A and
30% B was applied in the ﬁrst 15 min. After 15 min, a ratio of 50% A
and 50% B was used for the next 25 min. Finally, 5% A and 95% B
were used after 30 min for an additional 15 min. The solvent ﬂow
rate was 1 mL/min and the sample injection volume was 20 μL.
The UV–visible spectra were recorded in the wavelength range of
200–800 nm.
2.5.3. Spectrometric identiﬁcation
2.5.3.1. Isocoreopsin (2-(3, 4-Dihydroxy-phenyl)-7-(3, 4, 5-tri-
hydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-chroman-
4-one (1)).
UV: 217, 348, 367, 408 nm. ESI–MS: Isocoreopsin compound
displays a peak atm/z (M þ H)þ 435.36 (calcd m/z 434.39). 1H and
13C NMR data (400 and 100 MHz, DMSO- d6) (Table 1).
2.5.3.2. Butrin (2-[4-Hydroxy-3-(3, 4, 5-trihydroxy-6-hydro-
xymethyl-tetrahydro-pyran-2-yloxy)-phenyl]-7-(3, 4, 5-trihy-
droxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-chroman-4-
one (1)).
UV: 217, 329, 368 nm. ESI–MS: Butrin compound displays a
peak at m/z (M þNa)þ 619.2 (calcd m/z 619.16). 1H and 13C NMR
data (400 and 100 MHz, DMSO- d6) (Table 1).
2.5.3.3. Isobutrin (3-[4-Hydroxy-3-(3, 4, 5-trihydroxy-6-hydro-
xymethyl-tetrahydro-pyran-2-yloxy)-phenyl]-1-[2-hydroxy-4-(3,
4, 5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-phe-
nyl]-propenone).
UV: 217, 348, 367, 408 nm. ESI–MS: Isobutrin compound dis-
plays a peak at m/z (MþH)þ 597.1 (calcd m/z 596.17). 1H and 13C
NMR data (400 and 100 MHz, DMSO- d6) (Table 1).
2.6. Quantiﬁcation of bioactive compounds
2.6.1. Determination of total ﬂavonoids content
The total ﬂavonoids content of different extracted compounds
of B. monosperma ﬂowers were determined according to AlCl3
method. Different concentrations of each compound (2000 μg/mL)
were separately mixed with 0.1 mL of 10% AlCl3, 0.1 mL of 1 M
potassium acetate to a ﬁnal volume of 3 mL with distilled water,
followed by incubation for 30 min at room temperature. The
Table 1.
13C and 1H NMR spectroscopic data for compounds 1,2,3 with ESI–MS fragmenta-
tion ions.
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was substituted by the same amount of fraction in the blank.
Naringenin (100, 200, 300, 400, 500 and 1000 μg/mL) as a stan-
dard was used to make a calibration curve. The total ﬂavonoids
content of the compound was expressed as milligram acid
equivalents (Naringenin) per gram extract [22].
2.6.2. Evaluation of DPPH radical scavenging activity
The reaction mixture was prepared by dissolving dried ﬂower
extracts of 3 mg in 50% aqueous ethanol. About 100–500 μL of themixture was taken and made up to 750 μL with distilled water;
0.1 mM ethanolic DPPH solution was added to achieve a ﬁnal vo-
lume of 1.5 mL. Then the mixture was incubated in the dark at
room temperature for 30 min, and reduction of purple color was
read at 517 nm. Ascorbic acid present in solution A was used as a
standard and absolute ethanol as a blank. Radical scavenging ac-
tivity of isolated phenolic compounds was expressed as the per-
centage of inhibition of free radical and calculated using the fol-
lowing formula [23].
⎡⎣ ⎤⎦
( )
( )= − ×
DPPH scavenged %
Abs control Abs test /Abs control 100%
Where the Abs control is the absorbance of the control reac-
tion, whereas Abs test is the absorbance of the compound/
standard.
2.7. Experimental animals
Five-week-old male Wistar albino rats were obtained from In-
dian Institute of Science (IISC), Bangalore, India, and maintained in
our animal house in a ventilated, temperature-controlled room at
25 °C with 12/12 h light/dark cycle for 1–2 weeks prior to the ac-
tual commencements of the experiment. They were provided with
standard food pellets and drinking water (ad libitum). The proto-
col for the study was approved by Institutional Animal Ethics
Committee (IAEC), Bharathidasan University, Tiruchirappalli, Tamil
Nadu, India.
2.7.1. In vivo experimental protocol
Two protocols were designed for the evaluation of potential
chemo preventive agents against AOM induced colon cancer in
wistar albino rats [24]. In the ﬁrst protocol, wistar albino rats were
injected (subcutaneously) twice with AOM at the dosage of 15 mg/
kg during the ﬁrst two weeks of a ﬁve-week experimental period,
and the NBEs were administered (intraperitonial) during the
fourth week (two weeks after the last injection of AOM). This
protocol was used to evaluate the effects of the test compound
during the initiation phase in order to understand the carcinogen
metabolism. The second protocol was similar to the ﬁrst in most
respects except that the animals would not be exposed to the test
compounds until aberrant crypt foci (ACF) has grown in the colon
of the rats until the end of ﬁfth week. During the second two-week
period, the NBE was administered intraperitoneally to evaluate the
effects on outgrowth and progression of ACFs. Six groups of Wistar
albino rats (6 rats/group) were classiﬁed for treatment regimen
(Table 2). After the treatment period, the experimental animals
were sacriﬁced by intramuscular administration of ketamine
(90 mg/kg).
2.7.2. Histological observation of ACF formation
After treatment, 10–15 pieces of colonic tissues containing the
nodule shape of ACF were dissected from the mid-distal part of
each colon. They were placed in a petri dish containing saline
solution and were washed and dried to be embedded in parafﬁn
wax. These samples were sectioned parallel using a microtome
and stained with hematoxylin and eosin (HE). Histopathological
identiﬁcation of ACF was based on the criteria of multiplicity of
aberrant crypts. Multiplicity was determined as the number of
crypts in each focus and categorized as containing up to two, three
or more aberrant crypts/focuses. Fixed colorectal tumors were
processed and stained, and crypts were identiﬁed as described.
2.8. Cell viability assay
The human liver cancer cell line HepG2 and the human colon
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Centre for Cell Science (NCCS), Pune, India and cultured in DMEM
mediumwith supplementation of 10% FBS, penicillin, streptomycin
and fungizone. After 24 h of incubation in serum-free medium, the
cells were exposed to isolated pure compounds at the indicated
concentrations for 48 h for MTT assay. The cell viability of different
test compounds was determined using the equation: (OD570 of the
treated sample/OD570 of the untreated sample)100. All test
samples mentioned above were dissolved in DMSO. The ﬁnal
concentration of DMSO was o0.1% and 0.1% DMSO was used as
control.
2.9. Data analysis
All the experiments were conducted in triplicates. The results
were depicted as mean7SD (standard deviation). One way ANO-
VA was done by using SPSS version 16 and graph pad prism
software through Duncan's multiple range tests for comparing
means with signiﬁcance levels of po0.05 and po0.01.3. Results and discussion
3.1. NBE inhibiting property on ACF formation in AOM induced an-
imal model
To explicate the overall performance of isocoreopsin, butrin and
isobutrin, a well-established short- and long-term protocol was
used to determine NBE efﬁcacy on inhibiting ACF formation in AOM
induced rats. In terms of body weight, NBE did not show any con-
siderable changes among the various groups. During necropsy, no
pathologic alterations were found in any organs including the liver,
lungs, and kidneys. Moreover, the colonic ACF formation due to
AOM treatment was conﬁrmed under the observation of light mi-
croscope after HE staining (Fig. 1). The inhibitory effect of different
doses of NBE on AOM-induced colonic ACF formation is shown in
Fig. 2. Male Wistar albino rats injected with 50, 100 and 150 mg/kg
NBE showed signiﬁcant decrease in the number of total mean ACF/
colon (70%–80%; po0.01) compared with the rats injected with
AOM alone (Fig. 2). Whereas AOM induced rats contained three or
more aberrant crypts, which were reduced signiﬁcantly after the
treatment with NBE at 150 mg/kg when compared to silibinin
(positive control) treated group. These studies implied that NBE
exhibited a protective effect on AOM induced CRC.
3.2. Identiﬁcation of isocoreopsin, butrin and isobutrin from NBE
The NBE was subjected to 60–120 mesh size silica gel column
chromatogram to furnish two fractions and their purity was con-
ﬁrmed by HPTLC. The fraction I obtained from column chromato-
graphy contained only one compound (Compound 1). The HPTLC
results clearly indicated that the fraction II was conﬁrmed to be
isomerized compounds, butrin and isobutrin, with the Rf values of
0.68 and 0.65 min, respectively, when developed with methanol:Table 2.
Grouping of animals and dose of test agents against AOM induced colon cancer
animals.
Groups Test agent Dose (mg/kg)
Group 1 Saline only 0
Group 2 AOM only 15
Group 3 AOMþSilibinin 100
Group 4 AOMþ(n-butanol) extracts 50
Group 5 AOMþ(n-butanol) extracts 100
Group 6 AOMþ(n-butanol) extracts 150EtoAC (30:70, v/v). Further, the fraction II was subjected to reverse-
phase HPLC C18 column with acetonitrile as mobile phase. Initially,
it was shown that two inseparable peaks were very close to each
other at a retention time of 16 min, and then were separated by
using 0.1% phosphoric acid in mobile phase solution with the re-
tention time of 19.9 and 26.2 min. Surprisingly, these two puriﬁed
compounds were later found to be isomers (Compound 2 and 3)
(Fig. 3).
Compound 1 (Fig. 4) was obtained as a pale yellow amorphous
solid and had a molecular formula of C21H22O10 based on ESI–MS.
The IR spectrum of compound 1 indicated the presence of hy-
droxyl (3400 cm1) and carbonyl (1645 cm1) groups. The 1H
NMR spectrum evidenced signals assignable to seven multiple
protons at ä 0.70 and 1.05, a methylene group adjacent to ketone
at ä 2.05 and 2.25, all six D2O-exchangeable phenolic protons at ä
4.76 and 5.53, ﬁve aromatic protons appeared as multiplets at
ä 6.34 and 7.46 and another aromatic proton adjacent to ketone
appeared as multiplet at ä 7.69 and 7.77. Similarly, the 13C NMR
spectrum of compound 1 contained 21 signals indicating one
methylene (ä 28.9), one acyclic oxymethine (ä 60.7), four cyclic
oxymethines (ä 73.0 and 77.1), one oxygen-attached tertiary car-
bon and two aromatic oleﬁnic methines (ä 102.5), six aromatic
methines (ä 113.4, 115.3, 128.3 and 145.1), two aromatic tertiary
carbons (ä 163.0 and 164.6) and a ketone carbonyl carbon (ä
190.0). In addition, the ESI–MS fragmentation of compound 1 also
yielded the structural information. A fragment ion at m/z 273.07
(M – 162.05) occurred from loss of 2-(hyroxymethyl) tetrahydro-
2 h-pyran-3, 4, 5-triol group in compound 1. Our results indicated
that 1H and 13C NMR data of compound 1 signiﬁcantly resembled
those in Table 1. Thus, the structure of compound 1 was identiﬁed
as isocoreopsin (2-(3, 4-Dihydroxy-phenyl)-7-(3, 4, 5-trihydroxy-
6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-chroman-4-one (1)).
Compounds 2 and 3 were obtained as pale yellow thin ﬁlm and
the molecular formula were assigned to be C27H32O15 based on the
ion peak at 597 (MþNa)þ in the ESI–MS spectrum. The ESI–MS
spectrum of compound 2 gave two fragment ions as those of
compounds 1 and 3. The 1H and 13C NMR data of compound
2 signiﬁcantly resembled those in Table 1. Moreover, these results
coincided with the early report by Gupta et al. [25]. Thus, the
structure of compound 2 was identiﬁed as butrin (2-[4-Hydroxy-
3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-
phenyl]-7-(3, 4, 5-trihydroxy-6 hydroxymethyl-tetrahydro-pyran-
2-yloxy)-chroman-4-one (1)). Further, the yellow amorphous solid
of compound 3 was obtained and the ion peak at 597 (MþH)þ in
the ESI–MS spectrum indicated that this molecular formula could
be C27H32O15. Also, the ESI–MS spectrum of compound 3 imparted
two fragment ions. Interestingly, the 1H and 13C NMR data of
compound 3 considerably resembled those of the compounds in
Table 1. On the basis of the above results, the structure of com-
pound 3 was identiﬁed as isobutrin (3-[4-Hydroxy-3-(3, 4, 5-tri-
hydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-phenyl]-1-
[2-hydroxy-4-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyr-
an-2-yloxy)-phenyl]-propenone).
Our results demonstrated that three compounds in NBE were
identiﬁed and the most prominent among them was compound 1.
It would be interesting to know that the greater yield of com-
pound 1 from NBE may be a better source than the earlier report of
EtoAC extract. However, signiﬁcant amounts of compounds 2 and
3 were isolated as mentioned previously by Gupta et al. [25].
Surprisingly, isocoreopsin closely resembles silybin, silymarin and
quercetin, which show promising effects in treatment of various
diseases. This indicates that the full elucidation of extracted
compounds of B. monosperma ﬂowers focuses better insight into
its nutritional and medicinal properties.
Fig. 1. Histopathological examination of ACF formation in experimental groups (hematoxylin-eosin staining). (A) Normal colon, (B) ACF with single crypt, (C) ACF with dual
crypts, (D) ACF with three crypts, (E) Silibinin treated group (short term), (F) Silibinin treated group (long term), (G) NBE treated group (short term) and (H) NBE treated
group (long term).
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Previous studies have reported that the maximum concentra-
tion of ﬂavonoid (25.29%) is present in NBE rather than in theabsolute ethanol, methanol and other aqueous extracts [26,27]. In
this study, for the ﬁrst time, we have shown the ﬂavonoid contents
of all three compounds from NBE to access their bioactivity of each
individual. The ﬂavonoid contents of three different compounds of
Fig. 2. Effects of n-butanol extract (NBE) on aberrant crypt formation: (A) NBE effects on AOM induced short-term and (B) NBE effects on AOM induced long-term
experiment.
Fig. 3. HPLC results of butrin and isobutrin with retention time of 19.9 and
26.2 min, respectively.
Fig. 4. (A) Structure of isocoreopsin and (B) its fragmentation ion at m/z 272.
Table 3.
Flavonoid contents of B. monosperma ﬂower extract compounds.
Extract of B. monosperma ﬂowers Total ﬂavonoid (mg naringenin equiv/mg
extracts)
Isocoreopsin 79.8270.295a
Butrin 5.6870.286b
Isobutrin 9670.130c
a,b,cpo0.05 between the values.
Fig. 5. Dose-dependent DPPH free radical scavenging activity of compounds in
NBE.
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The HPLC fraction of isobutrin showed higher ﬂavonoid content
(96.0070.130) than those of other two compounds in NBE.
3.4. Free radical scavenging activity of NBE
Fig. 5 depicts the dose-dependent DPPH radical scavenging
activity of isolated compounds from NBE. Antioxidant substance
inhibited the spread of free radicals in biological systems by un-
dergoing a redox reaction with the phenolic compounds, which
might restrain the polymerization of free radicals and other oxi-
dizing reactions [28]. Based on the concentration, the phenolic
compounds established a dual mode of mechanism in antioxidant
(low concentration) and pro-oxidant (high concentration) effects
[29]. The EC50 values of extracts ranged from 10 to 50 μg/mL and
isocoreopsin of ﬂower extracts furnished the highest DPPH radicalscavenging activity with EC50 values of 10 μg/mL. The earlier re-
sults interpreted that butein had a strong antioxidant activity (87%
at 1 mg/mL) with EC50 value of 0.36 mg/mL when compared to
butrin (22%) [30]. These ﬁndings clearly indicate that the isolated
compounds from n-butanol have signiﬁcant activity at the mini-
mum dose. Since it has been suggested that ﬂavonoids are po-
tential antimutagenic, antiallergenic, antiviral, anti-inﬂammatory,
antioxidant, anticarcinogenic agents and are reported to induce
apoptosis, inhibit cell proliferation and angiogenesis [31]. From
these studies, it implies that these three active compounds may
have broader medical values, especially chemopreventive efﬁcacy
against human cancer.
Fig. 6. Anticancer activity of three compounds in NBE on (A) human colon cancer and (B) liver cancer cell lines at 48 h.
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All three compounds isolated in this study showed anti-
proliferative activity against HT-29 and HepG2 cell lines (Fig. 6).
However, signiﬁcant response was achieved for isocoreopsin with
the concentration of 50 μg/mL, followed by butrin and isobutrin
(100 μg/mL and 500 μg/mL) at 48 h. Our results also indicated that
isocoreopsin against HT-29 cell line revealed interesting differ-
ential antiproliferative activities with more than two fold effects
when compared to that for HepG2 cell line. Whereas, the butrin
(150 mg/mL) produced approximately similar results in both cell
lines and isobutrin (500 mg/mL) was signiﬁcantly less effective in
HepG2 cell line. Nevertheless, these results revealed that the
compound isocoreopsin has potential cytotoxicity in suppressing
colon and hepatocarcinoma cancer cell lines.
Wnt signaling gene is responsible for malignancies in colon,
rectum, skin, liver, brain and prostate cells, due to the activation of
β-Catenin [32]. Moreover, abnormal expression of GSK-3β (Glyco-
gen synthase kinase-3β), APC (Adenomatous polyposis coli) and β-
Catenin genes leads to down regulate the downstream targeted
genes of tumor suppressor genes and it has been observed in >90%
of colorectal cancer development. This implies that it has a pos-
sibility to inhibit Wnt/β-Catenin (HT-29) and NF-kB (HepG2) sig-
naling pathways. Interestingly, our results clearly indicated that
the individual compound exhibited cell-growth inhibition, when
compared to the earlier anticancer property of butein, butrin and
aqueous extracts of B. monosperma with different cancer cell lines
[33]. Our previous studies on silico docking demonstrated that the
active compounds, isobutrin, butrin and isocoreopsin, isolated
from B. monosperma ﬂowers have strong binding interaction with
Wnt β-catenin protein which is associated with CRC. Moreover, the
isocoreopsin obeyed the Lipinski rule of ﬁve parameters and ful-
ﬁlled the ADMET predictions. This proposes that it may have po-
tential anticancer activity against CRC [34,35].4. Conclusion
In the present study, the 150 mg/kg of NBE treated group
showed the strongest inhibitory effect and decreased the total
number of ACF formation (per rat) by 92% (short-term) and 78%
(long-term), respectively. These results suggest that the n-butanol
extracts may have potential chemopreventive efﬁcacy by inhibit-
ing ACF formation in colon and mainly contain three bioactive
compounds, namely isocoreopsin, butrin and isobutrin. The novel
glucoside isocoreopsin of NBE showed a better free radical
scavenging and anticancer activity. However, the ﬂavonoidcontents for these three different compounds differed sig-
niﬁcantly. Our results clearly illustrate the signiﬁcant anti-
proliferative effect of isocoreopsin on colorectal cancer cell line
and that it may be facilitated to target the subtype speciﬁc cancer
treatments in future. Further investigation on molecular pathways
of cancer targeted genes will be a worthy endeavor for better
understanding of the bioactive compounds from B. monosperma.Acknowledgments
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